I-MAB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.75 USD | -0.28% |
|
-5.41% | -7.89% |
| Apr. 18 | Verastem Names John Hayslip as Chief Medical Officer | MT |
| Apr. 15 | I-Mab Announces Chief Medical Officer Changes | CI |
Presenter SpeechTyler Ehler (Executives)Ladies and gentlemen, welcome to the Biopharma Financ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Companyâs pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.
Sector
Pharmaceuticals
Calendar
2024-08-26
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.755
USD
Average target price
7.25
USD
Spread / Average Target
+313.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.89% | 142M | |
| +38.67% | 705B | |
| +32.30% | 583B | |
| -2.72% | 364B | |
| +21.15% | 332B | |
| +6.44% | 291B | |
| +15.95% | 238B | |
| -3.52% | 210B | |
| +10.56% | 209B | |
| +9.73% | 169B |
- Stock Market
- Equities
- IMAB Stock
- News I-Mab
- Transcript : I-Mab, H1 2022 Earnings Call, Aug 30, 2022